ClinVar Miner

Submissions for variant NM_000297.4(PKD2):c.1094+3_1094+6del

dbSNP: rs1553925470
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 7
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV000697098 SCV000825689 likely pathogenic Autosomal dominant polycystic kidney disease 2020-01-07 criteria provided, single submitter clinical testing This variant has been observed in individual(s) with autosomal dominant polycystic kidney disease (PMID: 12707387, 30333007, 29529603). The variant is also known as IVS4+3del4 in the literature. ClinVar contains an entry for this variant (Variation ID: 434014). This variant is not present in population databases (ExAC no frequency). This sequence change falls in intron 4 of the PKD2 gene. It does not directly change the encoded amino acid sequence of the PKD2 protein, but it affects a nucleotide within the consensus splice site of the intron. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. Nucleotide substitutions within the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site, but this prediction has not been confirmed by published transcriptional studies.
Eurofins Ntd Llc (ga) RCV000728620 SCV000856217 pathogenic not provided 2017-08-18 criteria provided, single submitter clinical testing
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories RCV001001041 SCV001158156 pathogenic Polycystic kidney disease 2 2019-01-29 criteria provided, single submitter clinical testing The PKD2 c.1094+3_1094+6delAAGT variant has been described in multiple individuals and families affected with autosomal dominant polycystic kidney disease (ADPKD; see link to Mayo database, He 2018, Magistroni 2003, Rossetti 2007, Rossetti 2012). It contains an entry in ClinVar (Variation ID: 434014) and is absent from general population databases (Exome Variant Server and Genome Aggregation Database), indicating it is not a common polymorphism. This variant deletes four nucleotides of the consensus splice donor site within intron 4, and RNA studies have demonstrated a loss of the canonical splice donor site and incorporation of intron 4 into the sequence (Rossetti 2007). Based on available information, this variant is considered pathogenic. REFERENCES Link to Mayo ADPKD database: He W et al. Novel mutations of PKD genes in Chinese patients suffering from autosomal dominant polycystic kidney disease and seeking assisted reproduction. BMC Med Genet. 2018 Oct 17;19(1):186. Magistroni R et al. Genotype-renal function correlation in type 2 autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2003 May;14(5):1164-74. Rossetti S et al. Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2007 Jul;18(7):2143-60. Rossetti S et al. Identification of gene mutations in autosomal dominant polycystic kidney disease through targeted resequencing. J Am Soc Nephrol. 2012 May;23(5):915-33.
Fulgent Genetics, Fulgent Genetics RCV001001041 SCV002810877 pathogenic Polycystic kidney disease 2 2021-09-23 criteria provided, single submitter clinical testing
Ambry Genetics RCV002524141 SCV003745385 pathogenic Inborn genetic diseases 2022-11-29 criteria provided, single submitter clinical testing The c.1094+3_1094+6delAAGT variant results from a deletion of 4 nucleotides between positions c.1094+3 and c.1094+6 after coding exon 4 of the PKD2 gene. This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). This variant has been reported in several individuals with autosomal dominant polycystic kidney disease (Magistroni, 2003; Tan, 2009; Rossetti, 2012; He, 2018; Xu, 2018; Xu, 2021). In silico splice site analysis predicts that this alteration will weaken the native splice donor site. Based on the available evidence, this alteration is classified as pathogenic.
GeneDx RCV000728620 SCV004170065 likely pathogenic not provided 2023-10-09 criteria provided, single submitter clinical testing Published functional studies detect an altered transcript retaining all or a portion of intron 4 in a patient with the variant (Rossetti et al., 2007); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports a deleterious effect on splicing; This variant is associated with the following publications: (PMID: 12707387, 30333007, 29529603, 18837007, 34101167, 35778421, 22383692, 17582161)
Department of Pathology and Laboratory Medicine, Sinai Health System RCV000502098 SCV000592878 pathogenic Polycystic kidney disease no assertion criteria provided clinical testing The PKD2 c.1094+3_1094+6delAAGT variant was identified in 8 of 1056 proband chromosomes (frequency: 0.008) from individuals or families with ADPKD (Magistroni 2003, Tan 2009, Rossetti 2007, Rossetti 2012). Rosetti et al (2007) used RT-PCR analysis on lymphoblast cell lines to show that the variant abolished the normal donor site and the deletion produced a product that incorporated all or part of IVS4 into the sequence. In silico splicing models also confirm a splicing defect in a study characterizing the pathogenic potential of unclassified variants (Tan 2009). The variant was identified in the ADPKD Mutation Database (classification highly likely pathogenic), but was not identified in dbSNP, Clinvitae, ClinVar, GeneInsight COGR, PKD2-LOVD, 1000 Genomes Project, NHLBI GO Exome Sequencing Project, or in the Exome Aggregation Consortium database (March 14, 2016). The c.1094+3_1094+6delAAGT variant is located in the 5' splice region but does not affect the invariant +1 and +2 positions. However, positions +3 to +6 are part of the splicing consensus sequence and variants involving these positions sometimes affect splicing. In addition, 5 of 5 in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) predict a greater than 10% difference in splicing, predicting the abolishment of the 5’ consensus splice site. The variant is predicted to lead to a truncated or absent protein and loss of function. Loss of function variants of the PKD2 gene are an established mechanism of disease in autosomal dominant polycystic kidney disease and is the type of variant expected to cause the disorder. In summary, based on the above information, this variant meets our laboratory’s criteria to be classified as pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.